Synapse - Hematologic Malignancies, Division of

Results (13375)

Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3

Meeting Abstract

Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K. K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N. S.; Costa, L.; Vij, R.; more...
Blood (2023)

Fulltext@MSK | Save

Improved overall survival with axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma among the elderly: A subgroup analysis of ZUMA-7

Meeting Abstract

Kersten, M. J.; Farooq, U.; Rapoport, A. P.; Locke, F. L.; Leslie, L. A.; Ghobadi, A.; Miklos, D. B.; Jacobson, C. A.; Munoz, J. L.; Johnston, P. B.; more...
Blood (2023)

Fulltext@MSK | Save

Molecular taxonomy of myelodysplastic syndromes and its clinical implications

Meeting Abstract

Bernard, E.; Hasserjian, R.; Greenberg, P. L.; Ossa, J. E. A.; Creignou, M.; Nannya, Y.; Tuechler, H.; Medina-Martínez, J. S.; Levine, M. F.; Jädersten, M.; more...
Blood (2023)

Fulltext@MSK | Save

Long-term efficacy and safety of obecabtagene autoleucel (obe-cel) in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia ([R/R B-ALL]; Pooled analysis from ALLCAR19 and FELIX phase Ib studies) or other B-cell malignancies (ALLCAR19 extension study)

Meeting Abstract

Roddie, C.; Tholouli, E.; Shaughnessy, P.; Jabbour, E.; Logan, A. C.; Hodby, K.; Mountjoy, L.; Bloor, A. J. C.; Irvine, D.; Linch, D. C.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib in richter transformation: Updated efficacy and safety results with 18-month median survival follow-up from the phase 1/2 BRUIN study

Meeting Abstract

Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
Blood (2023)

Fulltext@MSK | Save

Long-term follow up for SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL)

Meeting Abstract

Advani, A. S.; Moseley, A. B.; O'Dwyer, K. M.; Wood, B. L.; Park, J. H.; Wieduwilt, M. J.; Jeyakumar, D.; Yaghmour, G.; Atallah, E. L.; Gerds, A. T.; more...
Blood (2023)

Fulltext@MSK | Save

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C)

Meeting Abstract

Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
Blood (2023)

Fulltext@MSK | Save

Phase 1/2 study of TP-3654, a selective PIM1 kinase inhibitor: Preliminary data showed clinical activity and cytokine reductions in relapsed/refractory myelofibrosis patients

Meeting Abstract

Rein, L. A. M.; El Chaer, F.; Yuda, J.; Shimoda, K.; McCloskey, J.; Takami, A.; Haque, T.; Ichii, M.; Shirane, S.; Fukaya, M.; more...
Blood (2023)

Fulltext@MSK | Save

Cryopreservation changes the immune effector cell composition of peripheral blood stem cell grafts: An analysis from the DKMS and NMDP graft composition study

Meeting Abstract

Rücker-Braun, E.; Falk, B.; Markey, K. A.; Minderman, H.; Baldauf, H.; Heymann, N.; Uhlemann, H.; Heiduschke, L.; MacMillan, H. R.; Newell, E. W.; more...
Blood (2023)

Fulltext@MSK | Save

Validation of the composite complete response (cCR) definitions in the International Working Group (IWG) 2023 criteria in patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) treated with hypomethylating agents (HMA) - A large, multicenter, retrospective analysis from the validate database

Meeting Abstract

Bewersdof, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
Blood (2023)

Fulltext@MSK | Save